2013
DOI: 10.1016/j.resp.2013.08.004
|View full text |Cite
|
Sign up to set email alerts
|

Effect of serum lipoproteins and cholesterol on an exogenous pulmonary surfactant. ESR analysis of structural changes and their relation with surfactant activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 54 publications
0
2
0
Order By: Relevance
“…Here, pulmonary surfactant reduces the surface tension in order to avoid collapse of alveolar architecture at the end of expiration and to assist the work of breathing [ 26 , 27 ]. A recent study found that, of all serum components individually tested, HDL cholesterol modified the surface properties of surfactant [ 28 ]. Another possibility is that HDL cholesterol inhibits tumor necrosis factor-alpha (TNF-α) stimulated sphingosine kinase activity in endothelial cells, resulting not only in decreased sphingosine 1-phosphate production but also increased ceramide [ 12 , 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Here, pulmonary surfactant reduces the surface tension in order to avoid collapse of alveolar architecture at the end of expiration and to assist the work of breathing [ 26 , 27 ]. A recent study found that, of all serum components individually tested, HDL cholesterol modified the surface properties of surfactant [ 28 ]. Another possibility is that HDL cholesterol inhibits tumor necrosis factor-alpha (TNF-α) stimulated sphingosine kinase activity in endothelial cells, resulting not only in decreased sphingosine 1-phosphate production but also increased ceramide [ 12 , 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Administration of exogenous surfactant has become standard therapy for infants with respiratory distress syndrome (RDS) or jaline membrane disease PROSURF has demonstrated in numerous clinical studies, using the appropriately marked product, a high distribution capacity at the alveolar level and resolution of respiratory failure. [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36], Fig. No adverse effects could be found related to the administration of surfactants.…”
Section: Pulmonary Surfactant (Ps) Adjuvant Therapy In Sars-cov-2mentioning
confidence: 99%